Key facts
- This page summarizes Keith Crandell's Form 4 filing for Boundless Bio, Inc. (BOLD).
- 12 reported transactions and 7 derivative rows are listed below.
- Accepted by SEC: 04 Apr 2024, 16:30.
Keith Crandell - 02 Apr 2024 Form 4 Insider Report for Boundless Bio, Inc. (BOLD)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- BOLD
- Reported as of
- 02 Apr 2024
- Net transaction value
- +$3,200,000
- SEC form
- 4
- Accepted by SEC
- 04 Apr 2024, 16:30:41 UTC
- Prior SEC filing
- 27 Mar 2024
- Next SEC filing
- 14 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Keith Crandell, By: Mark McDonnell, attorney in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Keith Crandell filed Form 4 for Boundless Bio, Inc. (BOLD) on 04 Apr 2024.
Change
- Previous filing in this sequence was filed on 27 Mar 2024.
- Current net transaction value: +$3,200,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BOLD
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +589,743
- Change %
- +2156%
- Price
- Shares after
- 617,092
- Date
- 02 Apr 2024
- Ownership
- See footnotes
- Footnotes
- F1, F2, F4
BOLD
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +787,545
- Change %
- +1920%
- Price
- Shares after
- 828,570
- Date
- 02 Apr 2024
- Ownership
- See footnotes
- Footnotes
- F1, F3, F4
BOLD
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,048,433
- Change %
- Price
- Shares after
- 1,048,433
- Date
- 02 Apr 2024
- Ownership
- See footnotes
- Footnotes
- F1, F5, F6
BOLD
transaction
Common Stock
Purchase
- Transaction value
- $1,066,672
- Shares
- +66,667
- Change %
- +11%
- Price
- $16.00*
- Shares after
- 683,759
- Date
- 02 Apr 2024
- Ownership
- See footnotes
- Footnotes
- F2, F4, F7
BOLD
transaction
Common Stock
Purchase
- Transaction value
- $2,133,328
- Shares
- +133,333
- Change %
- +13%
- Price
- $16.00*
- Shares after
- 1,181,766
- Date
- 02 Apr 2024
- Ownership
- See footnotes
- Footnotes
- F5, F6, F8
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BOLD
transaction
Derivative
Series A Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -424,908
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 02 Apr 2024
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 424,908
- Exercise price
- Footnotes
- F1, F2, F4
BOLD
transaction
Derivative
Series A Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -586,080
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 02 Apr 2024
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 586,080
- Exercise price
- Footnotes
- F1, F3, F4
BOLD
transaction
Derivative
Series A Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -454,212
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 02 Apr 2024
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 454,212
- Exercise price
- Footnotes
- F1, F5, F6
BOLD
transaction
Derivative
Series B Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -227,920
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 02 Apr 2024
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 227,920
- Exercise price
- Footnotes
- F1, F5, F6
BOLD
transaction
Derivative
Series C Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -164,835
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 02 Apr 2024
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 164,835
- Exercise price
- Footnotes
- F1, F2, F4
BOLD
transaction
Derivative
Series C Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -201,465
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 02 Apr 2024
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 201,465
- Exercise price
- Footnotes
- F1, F3, F4
BOLD
transaction
Derivative
Series C Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -366,301
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 02 Apr 2024
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 366,301
- Exercise price
- Footnotes
- F1, F5, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 8 footnotes
Footnote F1
Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.
Footnote F2
Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
Footnote F3
Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage.
Footnote F4
ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any.
Footnote F5
Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
Footnote F6
ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any.
Footnote F7
Reflects shares purchased by ARCH IX in the Issuer's initial public offering.
Footnote F8
Reflects shares purchased by ARCH X Overage in the Issuer's initial public offering.
SEC remarks
This Form 4 is one of two reports relating to the same transaction being filed jointly by ARCH IX, AVP IX LP, ARCH IX Overage, AVP IX Overage LP, AVP IX LLC, ARCH X Overage, AVP X Overage LP, AVP X LLC, Robert Nelsen, Keith Crandell, Steve Gillis and Clint Bybee (collectively, the "Reporting Persons"). Kristina Burow is filing her own Form 4 separately.